NCT05590130

Brief Summary

The investigators recently evaluated 4 different oximeters among the most commonly used with arterial catheter in place and compared SpO2 with SaO2 obtained on arterial gas. Correlations between SaO2 and SpO2 were poor for all oximeters, as previously known, and SpO2-SaO2 bias were different between oximeters. Some oximeters (Masimo, Nellcor) had lower biases but they detected less well hypoxemia. Some oximeters underestimated SaO2 (Nonin) but detected very well hypoxemia, and some overestimated SaO2 (Philips). The investigators concluded that oximeters provide different informations to clinicians, and oxygenation targets should take into account for these differences. The assumption is that the SpO2 target AND oximeter used will both have an impact on oxygen flows and that these effects will add up. With a high SpO2 target, oxygen flows will be significantly greater and with the Nonin oximeter, the required flows will be greater than with the Philips oximeter. NB: the results obtained were in a population with light skin pigmentation (96% of the patients were Fitzpatrick 1-2, reflecting the local hospitalized population).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
13mo left

Started Nov 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress77%
Nov 2022Jun 2027

First Submitted

Initial submission to the registry

October 14, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 21, 2022

Completed
26 days until next milestone

Study Start

First participant enrolled

November 16, 2022

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2027

Last Updated

September 4, 2025

Status Verified

August 1, 2025

Enrollment Period

4 years

First QC Date

October 14, 2022

Last Update Submit

August 27, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Oxygen flow (or FiO2)

    Oxygen flows (or FiO2) at the end of each study period (last minute average) to reach SpO2 target to reach SpO2 target with specific oximeter

    Mean Oxygen flow in the two last minute of each study period (between minute 8 and 10)

Secondary Outcomes (1)

  • Difference between SpO2 and SaO2

    assessed up to 10 minutes - at the same of the arterial blood gases punction

Other Outcomes (6)

  • Mean difference on oxymeter

    assessed up to 10 minutes - at the same of the arterial blood gases punction

  • Occult hypoxemia

    assessed up to 10 minutes - at the same of the arterial blood gases punction

  • Occult hyperoxemia

    assessed up to 10 minutes - at the same of the arterial blood gases punction

  • +3 more other outcomes

Study Arms (4)

Nonin oximeter with a 90% SpO2 target

EXPERIMENTAL

During this periods , oxygen will be administered in an manual titration with the FreeO2 device (fixed flow mode) to reach 90% of SpO2.

Device: Manual oxygen titration with Nonin oximeter (SpO2 target 90%)

Philips oximeter with a 90% SpO2 target

EXPERIMENTAL

During this periods, oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode), to reach 90% of SpO2.

Device: Manual Oxygen titration with Philips oximeter (SpO2 target 90%)

Nonin oximeter with a 94% SpO2 target

EXPERIMENTAL

During this periods , oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode) to reach 94% of SpO2.

Device: Manual oxygen titration with Nonin oximeter (SpO2 target 94%)

Philips oximeter with a 94% SpO2 target

EXPERIMENTAL

During this periods, oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode), to reach 94% of SpO2.

Device: Manual Oxygen titration with Philips oximeter (SpO2 target 94%)

Interventions

Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Philips oximeter

Philips oximeter with a 90% SpO2 target

Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Nonin oximeter

Nonin oximeter with a 90% SpO2 target

Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter

Philips oximeter with a 94% SpO2 target

Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter

Nonin oximeter with a 94% SpO2 target

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ≥ 18 years of age
  • Patients admitted to postoperative cardiac surgery intensive care unit
  • Presence of an arterial catheter Specific for the extubate patient
  • Ongoing on conventional oxygen therapy at moderate flow (up to a maximum of 5L/min) with SpO2 between 88 and 100% with the usual oximeter and nasal cannula.
  • SpO2 \< 92% ambient air Specific for the intubate patient FiO2 \<= 0.60 with SpO2 between 88 and 100% with usual oximeter SpO2 \< 92% with FiO2 0.21

You may not qualify if:

  • No SpO2 signal with oximeter in use
  • False nails or nail polish
  • Methemoglobinemia \>0.015 on last available arterial gas
  • Patient in isolation (multi-resistant bacteria, C-Difficile, SARS-CoV-2 ...) Specific for the extubate patient

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institut Universitaire de Cardiologie et de Pneumologie de Québec

Québec, Quebec, G1V4G5, Canada

RECRUITING

MeSH Terms

Conditions

Respiratory Insufficiency

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

October 14, 2022

First Posted

October 21, 2022

Study Start

November 16, 2022

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

June 1, 2027

Last Updated

September 4, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations